FCS’ Gordan Leads Study That Shows Community Oncology Practices Limit Financial Toxicity

A new study published in the American Journal of Public Health reveals that independent community oncology practices significantly reduce financial toxicity experienced by cancer patients compared to those treated in hospital outpatient settings.

Led by Lucio Gordan, MD, president and managing physician of Florida Cancer Specialists and Research Institute (FCS), the study analyzed real-world claims data to compare costs associated with cancer care in different settings. Financial toxicity refers to the economic burden of cancer treatment on patients and their families that negatively impacts their wellbeing.

The research found that the mean monthly cost of care in community oncology clinics was 24% lower than in hospital outpatient settings, with average costs of $12,548 versus $16,555 respectively. When focusing on branded chemotherapy, costs were 39% lower in community oncology at $6,674 compared to $10,900 in hospital-based clinics.

The cost differences are largely driven by lower drug markups, reduced facility fees, and more efficient care delivery in independent community practices. These factors contribute to significantly lower out-of-pocket expenses for patients. The study also notes that many health plans, including Medicare, do not cap out-of-pocket costs for infused drugs, further emphasizing the financial impact of drug markups in hospital settings.

“These findings reinforce what many of us in community oncology have long observed,” said Gordan. “Patients benefit not only from compassionate, personalized care close to home, but also from dramatically lower financial strain during one of the most difficult periods of their lives.”

Ted Okon, executive director of the Community Oncology Alliance (COA), which represents independent community practices, stated, “This new data reaffirms what COA has championed for years—that community oncology is the backbone of cancer care in this country, delivering better value and outcomes for patients. As policymakers and stakeholders evaluate solutions to rising cancer costs, it is critical that we do everything we can to support and strengthen the independent community oncology system.”